Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 27, 2015 Phillip Broadwith	Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases.
Managed Care April 2004 Jack McCain	Statin Therapy: More Than Meets the Eye? Statin selection has just become more complicated. Will physicians be diverted from interventions that may be less costly and just as effective?
American Family Physician March 15, 2005 Lockman et al.	Treatment of Cholesterol Abnormalities The relationship between coronary heart disease and elevated cholesterol levels has been recognized for many years, but now studies show an improvement in patient-oriented outcomes in patients receiving drug therapy.
American Family Physician January 15, 2001 Michael A. Crouch	Effective Use of Statins to Prevent Coronary Heart Disease Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein level can substantially reduce coronary events and death from coronary heart disease...
American Family Physician March 1, 2002 Richard S. Safeer	Cholesterol Treatment Guidelines Update In addition to modifying current strategies of risk assessment, the new guidelines stress the importance of an aggressive therapeutic approach in the management of hypercholesterolemia...
American Family Physician December 15, 2000 Alan J. Garber	Attenuating Cardiovascular Risk Factors in Patients with Type 2 Diabetes All cardiovascular risk factors except smoking are more prevalent in patients with type 2 diabetes. In addition to exercise, weight control, aspirin therapy and blood pressure control, therapy to modify lipid profiles is usually necessary...
CIO October 29, 2015 Martha Heller	Amgen uses algorithms to venture into digital healthcare A senior vice president of global marketing and commercial development, says she's working with the CIO to set up a digital healthcare organization that can help physicians better predict how patients will respond to therapies.
American Family Physician January 15, 2002 Lori J. Mosca	Optimal Management of Cholesterol Levels and the Prevention of Coronary Heart Disease in Women Elevated levels of low-density lipoprotein cholesterol and triglycerides and low levels of high-density lipoprotein cholesterol are significant risk factors for coronary heart disease. Abundant data show inadequate utilization of lipid-lowering therapy in women...
American Family Physician October 15, 2003 Morris & Tiller	Ezetimibe for Hypercholesterolemia Ezetimibe is safe and effective for lowering LDL cholesterol and triglyceride levels, but has not been shown to affect patient-oriented outcomes.
BusinessWeek April 19, 2004 Catherine Arnst	Cholesterol: How Low Should It Be? New studies say as low as possible, but drugs aren't for everybody
American Family Physician July 15, 2005 Lee Radosh	STEPS: Colesevelam (WelChol) for Reduction of LDL Cholesterol Colesevelam lowers LDL cholesterol levels a small amount (7% to 16%) when used alone and provides additional cholesterol lowering when added to statin therapy.
Nurse Practitioner July 2010 Kristine A. Scordo	Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease
The Motley Fool December 30, 2003 Arash Mostaghimi	Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers.
The Motley Fool April 2, 2008 Michael P. Cecil	Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite.
The Motley Fool December 23, 2003 Arash Mostaghimi	The Cholesterol Wars Who will win the fight to save your arteries? Fortunately for our corpulent country, pharmaceutical companies want to unclog our arteries -- and lighten our wallets. But which pharma stock will add to most girth to a portfolio?
American Family Physician January 15, 2001	Goals for Lowering Your Cholesterol Why is it important to have a normal cholesterol level?... What does the term "total cholesterol" mean?... Why is LDL called the "bad" cholesterol?... What are normal cholesterol levels?... How can I reduce my LDL and total cholesterol levels?... etc.
The Motley Fool April 21, 2011 Luke Timmerman	Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis.
BusinessWeek December 13, 2004 Kate Murphy	Cholesterol: The Bigger the Better Many doctors are convinced that getting a more thorough cholesterol test, one that identifies the types of LDL particles, can improve treatment and save lives.
The Motley Fool September 25, 2007 Brian Lawler	Amgen's European Adventures The European Medicines Agency announces that it has reversed its decision on Amgen's cancer drug Vectibix, allowing it on the market for a limited patient population. Investors, take note.
The Motley Fool August 25, 2008 Brian Lawler	Amgen Gets Its FDA Response Amgen investors can finally breathe a little sigh of relief after the biopharma giant announces that the Food and Drug Administration has finally approved its blood disorder drug.
BusinessWeek August 2, 2004 Carol Marie Cropper	Cholesterol Drugs: Not So Fast Do you have high low-density lipoprotein? A C-reactive protein test may help your doctor decide if it poses a threat.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
The Motley Fool March 17, 2008 Brian Lawler	The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared.
Nursing August 2008 Carl A. Kirton	Managing Long-Term Complications of HIV Infection Now that advances in treatment have transformed HIV into a chronic, manageable disease, patients are facing cardiovascular and metabolic complications you might not have expected 15 years ago. Here's how to help your patient manage them.
The Motley Fool May 29, 2007 Brian Lawler	Amgen Is Vexed The European Union medical authority says no to Amgen's cancer compound. Investors, take note.
Nutra Solutions April 1, 2005	Cholesterol-lowering Ingredient A recent study indicates that ImmunoLin has lowering effects on LDL cholesterol in mildly hypercholesterolemic adults.
Pharmaceutical Executive October 1, 2006 Rob Scott	Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug."
The Motley Fool October 19, 2009 Brian Orelli	Still Waiting for Its Blockbuster Amgen announces a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia, its treatment for postmenopausal osteoporosis.
American Family Physician October 15, 2003 Gavin et al.	Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels.
Nutrition Action Healthletter October 2001	Read My Lipids How to lower your risk of a heart attack...
BusinessWeek March 22, 2004 Arlene Weintraub	Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work?
The Motley Fool April 11, 2008 Brian Lawler	Amgen's Unsurprising Delay The FDA extends its review of an Amgen drug candidate.
The Motley Fool February 9, 2011 Luke Timmerman	Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"?
The Motley Fool October 21, 2004 W.D. Crotty	One Value-Priced Biotech Giant Amgen is a growing cash machine selling at the market's multiple to earnings.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
Pharmaceutical Executive July 3, 2007 Jessica DiPaolo	Toolkit: Good Tailoring Does your marketing campaign reach the huddled masses of frustrated or illiterate healthcare consumers?
Managed Care November 2004 Martin Sipkoff	OTC Status for Low-Dose Lovastatin Would Have Widespread Implications The FDA stands poised to approve OTC low-dose statins, following a similar change in United Kingdom.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
The Motley Fool February 29, 2008 Brian Lawler	Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs.
The Motley Fool October 29, 2007 Brian Lawler	Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader.
The Motley Fool September 10, 2007 Brian Lawler	Get a Glimpse of Amgen's Future Investors will want to pay attention to an FDA advisory panel meeting discussing new labeling recommendations for Amgen's anemia medications. The two drugs represented 44% of the pharmaceutical company's second-quarter revenue.
Chemistry World May 2008 Derek Lowe	In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is.
The Motley Fool November 16, 2009 Brian Orelli	Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference.
Chemistry World August 16, 2013 Paola Quattroni	Single molecule fights heart disease on two fronts Researchers in Israel have identified an antioxidant that can lower cholesterol levels as well as eliminating free radicals. This compound could be a promising alternative to statins, the most prescribed cholesterol-lowering drugs in the world.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors.
Chemistry World November 11, 2015 Maria Burke	Viral cancer therapy approved in the US The first virus therapy to target cancer has been approved in the US. Its main target will be melanoma, the most aggressive form of skin cancer.
Nutra Solutions April 1, 2006 Kerry Hughes	Additions to Heart Health The Portolio Eating Plan successfully assembles key nutritional ingredients known to lower cholesterol into one diet.
The Motley Fool March 19, 2008 Brian Lawler	Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera.